Summary: Evaluated sirolimus versus bare metal stents. The primary endpoint of major adverse cardiac events (cardiovascular death, nonfatal MI and target vessel revascularization) was reduced with sirolimus stents. There was reduced angiographic stenosis at 1 year.
N Engl J Med. 2002 Jun 6;346(23):1773-80.
Eponym: RAndomized Study with the Sirolimus-eluting VELocity Balloon Expandable Stent